FIELD: biotechnology.
SUBSTANCE: invention relates to a “cysteine-modified antibody-drug” conjugate with sites of cysteine embedding in a position 205 and/or a position 206 (Kabat numbering system) of an antibody light chain and/or a position 439 (Kabat numbering system) of a heavy chain. A “cysteine-modified antibody-drug” conjugate with good homogeneity is obtained by embedding cysteine (C) in the heavy chain and/or the light chain of the target antibody in the specific embedding site and performing site-specific conjugation using a free thiol group (-SH) of site-specific embedded cysteine and a linker conjugated with highly active low-molecular cytotoxin.
EFFECT: obtaining “cysteine-modified antibody-drug” conjugates.
9 cl, 28 dwg, 5 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
